Effect of FCGR2A and FCGR3A variants on CLL outcome.

Polymorphisms of activating Fc-γ receptors (FCGRs) on natural killer cells and macrophages result in variable affinity for immunoglobulin G1 monoclonal antibodies and subsequently modulate antibody-dependent cellular cytotoxicity (ADCC) activity. Whether single-nucleotide polymorphisms of FCGRs correlate with survival of chronic lymphocytic leukemia (CLL) patients treated with a monoclonal antibody containing regimen is unclear. We assessed the FCGR3A and FCGR2A genotype of patients enrolled in the REACH trial, where patients received fludarabine and cyclophosphamide (FC) or rituximab plus FC (R-FC). FCGR3A and FCGR2A polymorphisms did not demonstrate prognostic significance in the FC arm (P = .42 and P = .64, respectively) or R-FC arm (P = .41 and P = .88, respectively) with respect to progression free survival. Patients with intermediate affinity genotypes (FV and HR) benefited significantly from addition of rituximab (hazard ratio = 0.55 [0.37-0.8 CI]; P = .0017 and hazard ratio = 0.63 [0.44-0.9 CI]; P = .011, respectively). Similar benefit was suggested for patients with high- affinity VV and HH (hazard ratio = 0.86 [0.4-1.84 CI]; P = .7 and hazard ratio = 0.7 [0.41-1.18 CI]; P = .18, respectively) and low-affinity FF and RR (hazard ratio = 0.85 [0.56-1.29 CI]; P = .44 and hazard ratio = 0.82 [0.47-1.42 CI]; P = .48, respectively). Overall, our results suggest that FCGR2A and FCGR3A polymorphisms do not significantly influence the outcomes of relapsed or refractory CLL patients treated with FC or the monoclonal antibody regimen R-FC.

[1]  M. Ghielmini,et al.  Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Ganly,et al.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David Jarjoura,et al.  CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. , 2010, Blood.

[4]  T. Robak.  Improving FCR immunochemotherapy in CLL. , 2010, Blood.

[5]  L. Rimsza,et al.  Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone. , 2009 .

[6]  J. Zhi,et al.  Higher Doses of Rituximab May Be Required for Patients with CLL as Compared to NHL Based On Population Pharmacokinetic (PK) Modeling. , 2009 .

[7]  T. Robak.  GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. , 2009, Current opinion in investigational drugs.

[8]  H. Klingemann,et al.  Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.

[9]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[10]  P. Ganly,et al.  Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial , 2008 .

[11]  A. Berrebi,et al.  Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL) , 2008 .

[12]  T. Stankovic,et al.  Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. , 2008, Blood.

[13]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Bruno Cazin,et al.  Chronic lymphocytic leukaemia cells are efficiently killed by an anti‐CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16 , 2008, British journal of haematology.

[15]  R. Foà,et al.  FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab , 2007 .

[16]  B. Labar,et al.  FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma , 2007 .

[17]  F. Di Raimondo,et al.  The Efficacy of Rituximab plus Hyper-CVAD Regimen in Mantle Cell Lymphoma Is Independent of FCγRIIIa and FCγRIIa Polymorphisms , 2007 .

[18]  Yeon-Hee Park,et al.  FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. , 2006, Blood.

[19]  Anton Hagenbeek,et al.  Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity , 2006, Clinical Cancer Research.

[20]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[21]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Hervé Watier,et al.  From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.

[23]  M. Hallek,et al.  Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells , 2004, Annals of Hematology.

[24]  J. Byrd,et al.  FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia , 2004 .

[25]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Byrd,et al.  Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[28]  J. Byrd,et al.  The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. , 2002, Blood.

[29]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[30]  E. Vitetta,et al.  Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. , 2001, Blood.

[31]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[32]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[33]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[34]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[35]  D. Roos,et al.  FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .

[36]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[37]  M. Isturiz,et al.  Cyclophosphamide augments ADCC by increasing the expression of Fc-receptors. , 1987, Immunology letters.

[38]  H. Döhner,et al.  From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.

[39]  T. Robak,et al.  Current and emerging therapies for acute myeloid leukemia. , 2009, Clinical therapeutics.

[40]  M. Ghielmini,et al.  Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. , 2009, Journal of Clinical Oncology.

[41]  F. Di Raimondo,et al.  The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. , 2007, Journal of chemotherapy.

[42]  B. Labar,et al.  FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. , 2007, Haematologica.

[43]  R. Foà,et al.  FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. , 2007, Haematologica.

[44]  J. Byrd,et al.  Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. , 2004, Blood.

[45]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[46]  D. Roos,et al.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. , 1997, Blood.